Join Crinetics Pharmaceuticals for an in-person reception at ENDO 2024 to discuss the company’s clinical development programs for atumelnant* (CRN04894), a first-in-class, investigational, oral ACTH antagonist currently in development for the treatment of congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing’s syndrome.

The event will include a review of initial results from the ongoing clinical studies by Crinetics’ Chief Endocrinologist Alan Krasner, MD, and feature a fireside chat with global endocrinology expert Umasuthan Srirangalingam, MD (University College London Hospitals) that will be moderated by VP of Clinical Endocrinology, Peter Trainer, MD.

A live question and answer session will follow the formal presentation.

*Proposed international nonproprietary name under review.